CargoTek™ improves gene therapies by inducing a state of tolerance and dampening adverse pro-inflammatory reactions. Creating a state of "non-danger" for antigen presenting cells allows activation of Treg cells, a potent immune dampening cell that releases immunosuppressive cytokines.
For gene therapies, our platform strives for multiple dosing while also enhancing efficacy of the first dose. We broaden the eligible patient population and significantly add value to the therapeutic.
Our platform technology allows us to develop a robust portfolio of next-generation biologics. Our platform can also address unmet needs in other therapeutic areas, such as protein based-therapeutics, cell therapies, and/or transplants.